Intercept Pharma (ICPT) Tops Q1 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 6, 2021 7:00 AM EDTWorldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter
Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million to $340 million and reiterates Non-GAAP adjusted operating expense guidance of $380 to $410 million
Process between Intercept and FDA remains ongoing regarding updates to the Ocaliva U.S. Prescribing Information
Intercept continues to work toward potential resubmission of OCA in NASH fibrosis in the U.S.
Company to host conference call today at 8:30... More
